{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:14:27Z","timestamp":1761556467237,"version":"build-2065373602"},"reference-count":65,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["R01 DK080111","K23 DK085378"],"award-info":[{"award-number":["R01 DK080111","K23 DK085378"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.sapharm.2014.12.007","type":"journal-article","created":{"date-parts":[[2014,12,31]],"date-time":"2014-12-31T02:02:44Z","timestamp":1419991364000},"page":"824-843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Association between higher rates of cardioprotective drug use and survival in patients on dialysis"],"prefix":"10.1016","volume":"11","author":[{"given":"Yuexin","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B.","family":"Wetmore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa I.","family":"Shireman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.sapharm.2014.12.007_bib1","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2013.11.001","article-title":"US renal data system 2013 annual data report","volume":"63","author":"Collins","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.sapharm.2014.12.007_bib2","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jacc.2005.11.073","article-title":"Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials","volume":"47","author":"Al-Mallah","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.sapharm.2014.12.007_bib3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.sapharm.2014.12.007_bib4","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.sapharm.2014.12.007_bib5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJM199808203390801","article-title":"Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction","volume":"339","author":"Gottlieb","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sapharm.2014.12.007_bib6","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/archinte.166.7.787","article-title":"Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials","volume":"166","author":"Danchin","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.sapharm.2014.12.007_bib7","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0002-8703(03)00403-4","article-title":"Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials","volume":"146","author":"Haas","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.sapharm.2014.12.007_bib8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.7326\/0003-4819-141-9-200411020-00011","article-title":"Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction","volume":"141","author":"Lee","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.sapharm.2014.12.007_bib9","doi-asserted-by":"crossref","first-page":"593","DOI":"10.7326\/0003-4819-138-7-200304010-00018","article-title":"Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care","volume":"138","author":"Vijan","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.sapharm.2014.12.007_bib10","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","article-title":"A comparison of outcomes with angiotensin-converting\u2013enzyme inhibitors and diuretics for hypertension in the elderly","volume":"348","author":"Wing","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sapharm.2014.12.007_bib11","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","article-title":"Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial","volume":"289","author":"Black","year":"2003","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.sapharm.2014.12.007_bib12","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1136\/bmj.38793.468449.AE","article-title":"Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials","volume":"332","author":"Costa","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.sapharm.2014.12.007_bib13","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1161\/01.STR.0000092488.40085.15","article-title":"Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review","volume":"34","author":"Rashid","year":"2003","journal-title":"Stroke"},{"year":"2006","series-title":"AHA\/ACC Guidelines for Secondary Prevention for Patients with Coronary and Other Atherosclerotic Vascular Disease: 2006 Update","author":"Smith","key":"10.1016\/j.sapharm.2014.12.007_bib14"},{"key":"10.1016\/j.sapharm.2014.12.007_bib15","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1161\/01.HYP.0000174591.42889.a2","article-title":"Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention","volume":"46","author":"Verdecchia","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.sapharm.2014.12.007_bib16","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sapharm.2014.12.007_bib17","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in\u00a0reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial\u00a0(the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.sapharm.2014.12.007_bib18","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sapharm.2014.12.007_bib19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sapharm.2014.12.007_bib20","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/ndt\/gft515","article-title":"Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial","volume":"29","author":"Agarwal","year":"2014","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.sapharm.2014.12.007_bib21","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jacc.2010.03.105","article-title":"Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial","volume":"56","author":"Cice","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.sapharm.2014.12.007_bib22","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.ki.5001657","article-title":"Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies","volume":"70","author":"Zannad","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.sapharm.2014.12.007_bib23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.ajkd.2008.07.037","article-title":"The ABCs of cardioprotection in dialysis patients: a systematic review","volume":"53","author":"Wetmore","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.sapharm.2014.12.007_bib24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sapharm.2014.12.007_bib25","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.sapharm.2014.12.007_bib26","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.sapharm.2014.12.007_bib27","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1681\/ASN.2010090987","article-title":"Rosuvastatin in diabetic hemodialysis patients","volume":"22","author":"Holdaas","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.sapharm.2014.12.007_bib28","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/ndt\/gfs590","article-title":"Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial","volume":"28","author":"Iseki","year":"2013","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.sapharm.2014.12.007_bib29","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ahj.2011.05.004","article-title":"Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis","volume":"162","author":"Chang","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.sapharm.2014.12.007_bib30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","article-title":"Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis","volume":"157","author":"Palmer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.sapharm.2014.12.007_bib31","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1042\/cs1030511","article-title":"Association of calcium channel blockers and mortality in haemodialysis patients","volume":"103","author":"Tepel","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.sapharm.2014.12.007_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2013.03.007","article-title":"Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy\u2013a meta-analysis of 11 randomized controlled trials involving 21,295 participants","volume":"72","author":"Barylski","year":"2013","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.sapharm.2014.12.007_bib33","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/eurheartj\/eht065","article-title":"Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"34","author":"Hou","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.sapharm.2014.12.007_bib34","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients","volume":"45","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.sapharm.2014.12.007_bib35","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s11606-012-2112-7","article-title":"Geographic variation in HMG-CoA reductase inhibitor use in dialysis patients","volume":"27","author":"Wetmore","year":"2012","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.sapharm.2014.12.007_bib36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.ajkd.2011.02.387","article-title":"Geographic variation in cardioprotective antihypertensive medication usage in dialysis patients","volume":"58","author":"Wetmore","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.sapharm.2014.12.007_bib37","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1053\/j.ajkd.2011.10.047","article-title":"Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare part D","volume":"59","author":"Frankenfield","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.sapharm.2014.12.007_bib38","series-title":"Pharmacotherapy: A Pathophysiologic Approach","article-title":"Chapter 19. Hypertension","author":"Saseen","year":"2011"},{"key":"10.1016\/j.sapharm.2014.12.007_bib39","first-page":"2907","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of Cardiology\/American heart association task force on practice guidelines","volume":"63","author":"Stone","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.sapharm.2014.12.007_bib40","article-title":"Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.sapharm.2014.12.007_bib41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1198\/07350010152472571","article-title":"Estimation of limited dependent variable models with dummy endogenous regressors","volume":"19","author":"Angrist","year":"2001","journal-title":"J Business Economic Statistics"},{"key":"10.1016\/j.sapharm.2014.12.007_bib42","first-page":"467","article-title":"Identification and estimation of local average treatment effects","author":"Imbens","year":"1994","journal-title":"Econ J Econ Soc"},{"key":"10.1016\/j.sapharm.2014.12.007_bib43","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1046\/j.1523-1755.2002.00355.x","article-title":"Calcium channel blocker use and mortality among patients with end-stage renal disease","volume":"61","author":"Kestenbaum","year":"2002","journal-title":"Kidney Int"},{"year":"2012","series-title":"Introduction to Econometrics: Global Edition","author":"Stock","key":"10.1016\/j.sapharm.2014.12.007_bib44"},{"key":"10.1016\/j.sapharm.2014.12.007_bib45","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1475-6773.2003.00184.x","article-title":"Was breast conserving surgery underutilized for early stage breast cancer? Instrumental variables evidence for stage II patients from Iowa","volume":"38","author":"Brooks","year":"2003","journal-title":"Health Serv Res"},{"key":"10.1016\/j.sapharm.2014.12.007_bib46","first-page":"127854","article-title":"Survival implications associated with variation in mastectomy rates for early-staged breast cancer","volume":"2012","author":"Brooks","year":"2012","journal-title":"Int J Surg Oncol"},{"key":"10.1016\/j.sapharm.2014.12.007_bib47","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/MLR.0b013e3181e41bb2","article-title":"A new method to isolate local-area practice styles in prescription use as the basis for instrumental variables in comparative effectiveness research","volume":"48","author":"Fang","year":"2010","journal-title":"Med Care"},{"key":"10.1016\/j.sapharm.2014.12.007_bib48","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1001\/jama.1994.03520110039026","article-title":"Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables","volume":"272","author":"McClellan","year":"1994","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.sapharm.2014.12.007_bib49","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jama.297.3.278","article-title":"Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods","volume":"297","author":"Stukel","year":"2007","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.sapharm.2014.12.007_bib50","first-page":"591","article-title":"Tests of equality between sets of coefficients in two linear regressions","author":"Chow","year":"1960","journal-title":"Econ J Econ Soc"},{"key":"10.1016\/j.sapharm.2014.12.007_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev.publhealth.19.1.17","article-title":"Econometrics in outcomes research: the use of instrumental variables","volume":"19","author":"Newhouse","year":"1998","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.sapharm.2014.12.007_bib52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0895-4356(92)90016-G","article-title":"A chronic disease score from automated pharmacy data","volume":"45","author":"Von Korff","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.sapharm.2014.12.007_bib53","first-page":"1337","article-title":"Who is the marginal patient? Understanding instrumental variables estimates of treatment effects","volume":"33","author":"Harris","year":"1998","journal-title":"Health Serv Res"},{"key":"10.1016\/j.sapharm.2014.12.007_bib54","first-page":"1061","article-title":"Overview of the special supplement issue","volume":"35","author":"McClellan","year":"2000","journal-title":"Health Serv Res"},{"key":"10.1016\/j.sapharm.2014.12.007_bib55","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2307\/2171753","article-title":"Instrumental variables regression with weak instruments","author":"Staiger","year":"1997","journal-title":"Econometrica"},{"key":"10.1016\/j.sapharm.2014.12.007_bib56","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/01621459.1960.10483365","article-title":"On finite sample distributions of generalized classical linear identifiability test statistics","volume":"55","author":"Basmann","year":"1960","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.sapharm.2014.12.007_bib57","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/aje\/kwr283","article-title":"Apples and oranges? Interpretations of risk adjustment and instrumental variable estimates of intended treatment effects using observational data","volume":"175","author":"Fang","year":"2012","journal-title":"Am J Epidemiol"},{"year":"2002","series-title":"Econometric Analysis of Cross Section and Panel Data","author":"Wooldridge","key":"10.1016\/j.sapharm.2014.12.007_bib58"},{"key":"10.1016\/j.sapharm.2014.12.007_bib59","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1093\/ndt\/gfn304","article-title":"Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients","volume":"23","author":"Tepel","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.sapharm.2014.12.007_bib60","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/ndt\/gfh280","article-title":"Medication prescribing patterns in ambulatory haemodialysis patients: Comparisons of USRDS to a large not-for-profit dialysis provider","volume":"19","author":"Manley","year":"2004","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.sapharm.2014.12.007_bib61","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/ajhp\/61.14.1473","article-title":"Patterns of antihypertensive medication use in hemodialysis patients","volume":"61","author":"Rahman","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.sapharm.2014.12.007_bib62","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1162\/rest.88.3.389","article-title":"Understanding instrumental variables in models with essential heterogeneity","volume":"88","author":"Heckman","year":"2006","journal-title":"Rev Econ Stat"},{"key":"10.1016\/j.sapharm.2014.12.007_bib63","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.sapharm.2014.12.007_bib64","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/hr.2009.184","article-title":"Reinventing the ACE inhibitors: some old and new implications of ACE inhibition","volume":"33","author":"Hanif","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1016\/j.sapharm.2014.12.007_bib65","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.ehj.2004.06.003","article-title":"Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The task force on ACE-inhibitors of the european society of cardiology","volume":"25","author":"Lopez-Sendon","year":"2004","journal-title":"Eur Heart J"}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741114004136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741114004136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:10:36Z","timestamp":1761556236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551741114004136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1551741114004136"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2014.12.007","relation":{},"ISSN":["1551-7411"],"issn-type":[{"type":"print","value":"1551-7411"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between higher rates of cardioprotective drug use and survival in patients on dialysis","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2014.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}